Dr. Eng Discusses the Ongoing FRESCO-2 Trial in mCRC

Cathy Eng, MD, FACP, FASCO, David H. Johnson Chair in Surgical and Medical Oncology, co-leader of the Gastrointestinal (GI) Cancer Research Program, professor of medicine in hematology and oncology, co-director of GI Oncology, vice chair of the SWOG GI Committee, and director of the VICC Young Adult Cancers Initiative at Vanderbilt-Ingram Cancer Center, discusses the ongoing phase 3 FRESCO-2 trial (NCT04322539) in metastatic colorectal cancer (mCRC).

The global, double-blind, placebo-controlled FRESCO-2 trial is randomizing patients with mCRC 2:1 to fruquintinib plus best supportive care vs placebo plus best supportive care. Eligible patients had to have received prior regorafenib (Stivarga) and/or trifluridine/tipiracil (TAS-102; Lonsurf). The primary end point of the study is overall survival, Eng explains.

Fruquintinib is a potent, highly selective, oral VEGF1/2/3 TKI that is approved in China to treat patients with mCRC who have been previously treated with fluoropyrimidine, oxaliplatin, and irinotecan. In the United States, the FDA granted a fast track designation to fruquintinib for the treatment of patients with mCRC who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, VEGF-directed therapy, and if RAS wild-type, EGFR-directed therapy.